July 31, 2012 (Investorideas.com Newswire) - eResearch Corp reports The first of Bioniche Life Sciences Inc.'s two canine oncology products has received approval from regulators in both Canada and the USA.
The Company has begun market launch activities, and the product - Immunocidin™ - is expected to be available in September 2012 in Canada. A U.S. launch is expected before the end of the year.
Immunocidin™ is based on Bioniche's proprietary cell wall technology, which is derived from the same platform as the Company's Phase III product for human bladder cancer. Immunocidin™ is indicated as an immunotherapy for the intra-tumoral treatment of canine mixed mammary tumour and mammary adenocarcinoma.
Canine cancer is the leading disease-related cause of death in dogs - about one in four dogs dies of cancer. Human chemotherapy is commonly used for treatment of canine cancer, but side effects can affect a dog's quality of life.
Bioniche's Second Canine Therapy
The Company is undertaking dose-confirmation studies for its second canine cancer therapy - an intravenous (I.V.) therapy - before conducting final licensing studies. This work is expected to be completed over the next six to nine months, and then regulatory approvals will be sought (first in North America, then in Australia and Europe).
This news is published on the Investorideas.com Newswire and its syndicated partner network
News now!
Get Free investor news and stock alerts:
Sign up here
Disclaimer: The following news is paid for and /or published as information only for our readers.Investorideas.com is a third party publisher of news and research. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All Investment involves risk and possible loss of all investment. Disclaimer in full, Investorideas.com Disclosure Please read individual disclosures for featured stocks.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info
